Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Transdermal — Net revenue

Other product segments

Subtotal dosage forms
$482.3M+11.8%
Oral solid
$175.17M-1.7%
Subtotal therapeutic classes
$149.3M+17.1%
Central nervous system
$95.34M+14.3%
Distribution
$86.93M-12.8%
Other dosage forms
$81.59M+19.7%
Auto-Injector
$62.21M-6.6%
Injectable
$56.78M+63.9%
Government label
$50.21M+10.5%
Hormonal / allergy
$42.1M+18.9%
Biosimilar
$29.13M+15.4%
Institutional
$12.11M+19.5%
Other therapeutic classes
$11.85M+36.2%
Oral liquid
$10.37M-42.0%
International
$7.61M+300%
License agreement
$0-100%

Similar metrics at other companies

Installed Building Products logo
IBPNet revenue, Installation — Net revenue
$710.7M-0.7%
Marqeta logo
MQPlatform services revenue, net — Net revenue
$156.23M+18.5%
Visa logo
VOther revenue — Net revenue
$1.5B+45.5%
Visa logo
VService revenue — Net revenue
$4.92B+13.7%
Cavco Industries logo
CVCODelivery, setup and other revenues — Net revenue
$23.21M-15.9%
Marqeta logo
MQOther services revenue — Net revenue
$9.57M+32.8%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×—
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Affordable Medicines
Oral solid$175,172$178,262$346,272$357,215
Transdermal67,03840,710141,00183,773
Auto-Injector62,21466,594104,126114,754
Injectable56,78334,646106,72169,434
Biosimilar29,12825,24851,42953,788
Oral liquid10,37117,87922,46341,427
Other dosage forms (1)81,59468,185128,206124,607

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s transdermal — net revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported transdermal — net revenue of $67.04M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s transdermal — net revenue changed year-over-year?
Amneal Pharmaceuticals, Inc.'s transdermal — net revenue increased by 64.7% year-over-year, from $40.71M to $67.04M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s transdermal — net revenue?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s transdermal — net revenue has grown at a 16.3% compound annual growth rate (CAGR), from $119.29M to $187.51M.
What does transdermal — net revenue mean?
This metric represents the total gross sales generated from transdermal drug delivery products after accounting for returns, allowances, and rebates. It serves as a key indicator of the market demand and commercial performance for the company's specialized patch-based pharmaceutical portfolio. Monitoring this revenue stream helps investors assess the growth trajectory and competitive positioning of the company's non-oral drug delivery segment.

Ask your AI about Amneal Pharmaceuticals, Inc.'s transdermal — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude